CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Onco News
Dermabase.it

Chronic kidney disease is associated with an increased risk of both bleeding and ischemic cardiovascular events. The purpose of this study was to determine the balance of risks and benefits from th ...


Patients with chronic coronary artery disease ( CAD ) or peripheral artery disease ( PAD ) and history of heart failure ( HF ) are at high risk for major adverse cardiovascular events ( MACE ). Re ...


Patients with left-sided heart failure who get implanted devices to improve the pumping of their hearts may be more likely to develop heart failure on the opposite side of their hearts if they are pre ...


Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of Sacubitril - Valsartan ( Entresto ) therapy is safe and eff ...


EMPRISE is a study program on the effectiveness, safety and healthcare utilization of Empagliflozin ( Jardiance ), a SGLT2 inhibitor ( SGLT2i ), in routine care across a spectrum of cardiovascular bas ...


The results from an independent retrospective comparative study, published in the American Journal of Medicine, have shown that Dabigatran was associated with a more favourable benefit-harm profile th ...


Nonvitamin K antagonist oral anticoagulants ( NOACs ) are alternatives to Warfarin ( Coumadin ) in patients with nonvalvular atrial fibrillation. Randomized trials compared NOACs with Warfarin, but ...


The ODYSSEY OUTCOMES ( Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab ) trial compared Alirocumab ( Praluent ) with placebo, added to high-inte ...


Inhibition of the P2Y12 receptor by an oral P2Y12 inhibitor with loading doses along with cyclooxygenase-1 inhibition by Aspirin Acetylsalicylic acid ) is considered a first-line treatment strategy in ...


Thiazide, a first-line therapy for hypertension, lowers blood pressure, increases bone mineral density, and reduces the risk of fractures. However, hyponatremia, an adverse effect of thiazide, is as ...


In pulmonary arterial hypertension ( PAH ), combination therapy is an important treatment strategy. Although randomized controlled trial data are available to support the combination of two therapie ...


The chymase inhibitor Fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction ( LVD ) after acute m ...


The aim of a population-based cohort study was to determine whether the use of angiotensin converting enzyme inhibitors ( ACEIs ), compared with use of angiotensin receptor blockers, is associated wit ...


HeartMate 3 Left Ventricular Assist Device ( LVAD ) has received U.S. Food and Drug Administration ( FDA ) clearance as a destination therapy for people living with advanced heart failure. With th ...


In acute coronary syndrome ( ACS ), potassium imbalance at admission has been associated with in-hospital arrhythmias, cardiac arrest, and mortality. However, several important presentation characte ...